Hengrui Medicine Files for Dalpiciclib as Initial Therapy for Breast Cancer
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced a supplementary market filing for...
HitGen Partners with C4X Discovery to Identify Novel Inflammatory Disease Treatments
China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc...
Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance
With the Q3 2022 reporting season underway, US-based medtech giant Abbott (NYSE: ABT) released its...
Shaanxi Releases Notice for Inter-Provincial Orthodontic Brackets VBP
The Shaanxi Public Resources Trading Center has released the “Inter-provincial Alliance (regions, Corps) Orthodontic Brackets...
Hainan Poly Pharm’s Generic Ganciclovir Approved in Sweden for CMV Retinitis
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving technical review approval from...
Bio-Thera’s BAT1806 Biosimilar Accepted for Review by European Medicine Agency
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that a Biologic License Application (BLA) for...
Kactus Biosystems Raises RMB 200M in Series B Financing for Protein and Enzyme Development
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has raised RMB...
Shandong Junxiu Biotechnology Secures RMB 45M in Series B Financing
Shandong Junxiu Biotechnology Co., Ltd, a China-based maker of implantable regenerative medicine devices, has raised...
Brii Biosciences Reports Positive Phase I Results for HIV Treatments BRII-732 and BRII-778
China-based Brii Biosciences Limited (HKG: 2137) has published the latest results of two Phase I...
Bayer to Set Up Shenzhen Unit to Boost Women’s Healthcare in South China
Bayer’s (ETR: BAYN) women’s healthcare unit for the South China region is reportedly planning to...
GenScript’s Legend Biotech Reports USD 55M in Carvykti Sales
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that sales of...
YiChang HEC ChangJiang Pharma’s Insulin Aspart Gains NMPA Approval
China-based firm YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that its in-house...
Henlius Biotech’s Hanbeitai Gains NMPA Approval for Recurrent Glioblastoma
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...
NHSA Responds to Proposal on Dental Implants’ Inclusion in NRDL
The National Healthcare Security Administration (NHSA) has responded to the No. 6184 suggestion from the...
Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance
US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing...
Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion
China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO)...
Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for...
Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea
Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study...
Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion
Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...
Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into...